The Journal of Immunology

J Immunol. 2025 Apr 21:vkaf053. doi: 10.1093/jimmun/vkaf053. Online ahead of print. ABSTRACT The complement system is an essential part of innate immunity, and dysregulated complement is an underlying driver in many inflammatory and autoimmune diseases. Currently approved complement-focused therapeutics rely on systemic blockade of complement activation, but a major challenge with this approach is that … Read more

J Immunol. 2025 Apr 21:vkaf061. doi: 10.1093/jimmun/vkaf061. Online ahead of print. ABSTRACT This review explores interleukin (IL)-17D and its receptor CD93, highlighting their structural, functional, and clinical aspects. Identifying CD93 as the receptor for IL-17D has advanced understanding of the IL-17 family and its signaling pathways. IL-17D, with its unique glycoprotein structure, plays diverse roles … Read more

J Immunol. 2025 Apr 21:vkaf051. doi: 10.1093/jimmun/vkaf051. Online ahead of print. ABSTRACT Type 1 innate lymphoid cells (ILC1s) and conventional natural killer cells belong to the group 1 ILCs (gILC1), characterized largely by T-bet expression and interferon γ secretion. While much has been done to define factors that regulate the development, differentiation, and effector functions … Read more

J Immunol. 2025 Apr 18:vkaf046. doi: 10.1093/jimmun/vkaf046. Online ahead of print. ABSTRACT T helper cell differentiation is one of the key developmental events in the peripheral immune regulations, resulting in better adaptation to the nature of infection and inflammation. While it is known that several factors are involved in this differentiation, including subsets of antigen-presenting … Read more

J Immunol. 2025 Apr 18:vkaf042. doi: 10.1093/jimmun/vkaf042. Online ahead of print. ABSTRACT Inflammasomes are multiprotein innate immune complexes formed in response to infections, tissue damage, or cellular stress that promote the maturation and release of IL-1β/IL-18 and are implicated in lytic cell death. The NLRP3 inflammasome is canonically activated by an initial priming event followed … Read more

J Immunol. 2025 Apr 17:vkaf036. doi: 10.1093/jimmun/vkaf036. Online ahead of print. ABSTRACT Natural killer (NK) cells are emerging as a promising tool for cancer immunotherapy due to their innate ability to selectively recognize and eliminate cancer cells. Over the past 3 decades, strategies to harness NK cells have included cytokines, small molecules, antibodies, and the … Read more

J Immunol. 2025 Apr 15:vkae040. doi: 10.1093/jimmun/vkae040. Online ahead of print. ABSTRACT In people living with human immunodeficiency virus (HIV, PLWH), the coronavirus disease 2019 (COVID-19) vaccine often results in a limited humoral immune response. While a reduced absolute CD4+ T cell count is a known factor, other determinants remain unclear. To investigate variables influencing … Read more

J Immunol. 2025 Apr 15:vkaf032. doi: 10.1093/jimmun/vkaf032. Online ahead of print. ABSTRACT Despite pigs being an important species in influenza A virus (IAV) epidemiology and a reliable preclinical model for human IAV infections, many aspects of the porcine pulmonary immune system remain poorly understood. Here, we characterized the single-cell landscape of lung leukocytes of healthy … Read more

J Immunol. 2025 Apr 15:vkaf040. doi: 10.1093/jimmun/vkaf040. Online ahead of print. ABSTRACT Inducible Co-Stimulator (ICOS), as a T-cell-specific costimulatory receptor that enhances T-cell responses to foreign antigens, plays a crucial role in cancer immunity. However, its role in MSS/pMMR colorectal cancer (CRC) remains unclear. In this study, we demonstrated that ICOS expression decreases as the … Read more

J Immunol. 2025 Apr 10:vkaf047. doi: 10.1093/jimmun/vkaf047. Online ahead of print. ABSTRACT Chimeric antigen receptor T (CART) cell therapy is an innovative form of immunotherapy that has shown remarkable and long-term responses in patients with B-cell malignancies. Over the years, the field has made significant progress in our understanding of the successes and challenges associated … Read more